Septic Shock / Angiotensin II Infusion · Phase 4 Trial

Early Angiotensin II in the Emergency Department

ClinicalTrials.gov · September 2, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registered Phase 4 pilot study, currently recruiting, designed to assess the feasibility of early peripheral angiotensin II infusion in patients with septic shock presenting to the emergency department. No results have been posted to the registry; the study is evaluating operational and procedural feasibility over a 6-hour treatment window, not clinical efficacy or safety outcomes.

What was studied

Phase 4, Interventional, Non Randomized, Single Group, Open label, Treatment purpose. Septic Shock; age from 18 Years; to 99 Years. Intervention: Angiotensin II Infusion. n = 20. 1 site: United States.

Key findings

Safety

Primary outcome is feasibility, not efficacy or safety; clinical benefit is not measured.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an active, unstarted pilot trial registered to assess feasibility of an intervention in septic shock; no results are yet reported.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Feasibility of completing all clinical trial activities (assessed at From enrollment to the end of treatment up to 6 hours after the angiotensin II…)

DesignPhase 4, Interventional, Non Randomized, Single Group, Open label, Treatment purpose

PopulationSeptic Shock; age from 18 Years; to 99 Years

Sample size20

InterventionAngiotensin II Infusion

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment20

Primary outcome measureFeasibility of completing all clinical trial activities from enrollment to end of treatment up to 6 hours after angiotensin II infusion initiated

Study phasePhase 4

Recruitment statusRECRUITING

Caveats

This is a registry record only; no results have been posted or published.
Primary outcome is feasibility, not efficacy or safety; clinical benefit is not measured.
Single-arm design without control group; no comparative evidence reported.
Sample size is small (n=20 planned); follow-up duration limited to 6 hours post-infusion initiation.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Single-arm pilot study with feasibility primary outcome; interventional design specified.

Directness

moderate

Emergency department population with septic shock requiring vasopressor support; feasibility endpoint is surrogate.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

No results posted; blinding, allocation concealment, or outcome adjudication not stated.

Sample adequacy

limited

Planned enrollment 20 participants; pilot feasibility study with small target sample.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06693726). This is a study registration, not published results. Lead sponsor: Brett A Faine. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Septic Shock. Interventions: DRUG: Angiotensin II Infusion. Primary outcome measures: Feasibility of completing all clinical trial activities , From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated. Brief summary: This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Brett A FaineSeptic ShockAngiotensin II InfusionNCT06693726